Boehringer Ingelheim Pharmaceuticals brings a little German drugmaking know-how to the USA. The firm is the pharmaceuticals unit of Boehringer Ingelheim Corporation, which is the US headquarters of Germany's Boehringer Ingelheim. It sells a range of drugs in the US market, including prescription products (respiratory treatment Spiriva, high blood pressure medication Micardis, enlarged prostate treatment Flomax, Parkinson's disease drug Mirapex, and HIV/AIDS product Aptivus) and over-the-counter products (heartburn aid Zantac and constipation drug Ducolax). It is also an R&D center for Boehringer Ingelheim, specializing in immunology, inflammatory conditions, and cardiovascular disease.
The cardiovascular disease department is focused on new treatments for heart failure, hypertension, and atherosclerosis (a thickening of the arterial wall). The immunology and inflammation department seeks to uncover the mechanisms responsible for rheumatoid arthritis, multiple sclerosis, and psoriasis.
In 2014, Boehringer Ingelheim Pharmaceuticals and Eli Lilly received FDA approval for their Jardiance tablets to improve blood glucose levels in adults with type 2 diabetes. The FDA also approved the firm's Pradaxa for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.
Mergers and Acquisitions
Boehringer Ingelheim Pharmaceuticals has also expanded its pipeline through acquisitions, such as the purchase of the US rights to over-the-counter gastrointestinal treatment Zantac from Johnson & Johnson/Pfizer at a cost of more than half a billion dollars.